Summary DMXAA (5,6-dimethylxanthenone-4-acetic acid), a novel anti-tumour agent currently undergoing clinical evaluation. appears to mediate its anti-tumour effects through immune modulation and the production of the cytokine tumour necrosis factor-a (TNF). Our previous studies have shown that thalidomide, a potent inhibitor of TNF biosynthesis that has numerous biological effects, including inhibition of tumour angiogenesis. unexpectedly augments the anti-tumour response in mice to DMXAA. We show here that thalidomide (100 mg kg-) has no effect when administered with inactive doses of DMXAA, and that it must be given simultaneously with an active dose of DMXAA to have its maximum potentiating effect on the growth of the munne Colon 38 adenocarcinoma. To address the issue of whether inhibition of serum TNF production is important for potentiation of anti-tumour activity, we have tested three potent analogues of thalidomide. All three analogues. when co-administered with DMXAA to mice at doses lower than those used with thalidomide, inhibited TNF production and were effective in potentiating the anti-tumour activity of DMXAA against transplanted Colon 38 tumours. One of the analogues, N-phenethyltetrafluorophthalimide. was 1000-fold more potent than thalidomide and at a dose of 0.1 mg kg-' in combination with DMXAA (30 mg kg-') cured 1000 of mice. compared with 670o for the group treated with DMXAA alone. We also tested pentoxifylline and found it to suppress TNF production in response to DMXAA and to potentiate the anti-tumour effect of DMXAA. The results are compatible with the hypothesis that pharmacological reduction of serum TNF levels might benefit the anti-tumour effects of DMXAA and suggest new strategies for therapy using this agent.
drug flax one acetic acid (FAA that are highly actix e against transplantable murine tumours w-ith an established Xasculature (Rex-castle et al. 1989 (Rex-castle et al. . 1991 . The most potent of these. 5.6-dimethN-lxanthenone4-acetic acid (DMXAA) . is now-in phase I clinical trials in New Zealand and the UK. In mice. DNIXAA is 12-fold more potent than FAA and induces a higher percentage of cures acainst the Colon 38 carcinoma (Rexwcastle et al. 1991) .
DNIXAA and FAA share a mechanism of action that is different from that of conventional direct cvtotoxic anti-cancer drugs. Both appear to actix-ate. through host and tumour cell components. a complex series of responses involving shutdow n of tumour blood floxw (Z"-i et al. 1989. 1994) . stimulation of immune responses Bagulev. 1987: Ching et al. 1991 ) and elimination of the tumour.
NManv of the biolo2ical actix-ities of DMNXAA and FAA have been attributed to their abilitv to induce cxtokines. in particular TNF and the interferons (Mace et al. 1990 : Futami et al. 1992: be mediated by tumour necrosis factor-a (TNT) as antibodies to T-NF ablate FAA-induced tumour x-ascular collapse (Mahadex an et al. 1990 ). DMXAA induces hiaher lexels of serum TNF than FAA. and the anti-tumour response correlates w ell w-ith TNF production w ithin a series of DMXAA analoaues (Philpott et al. 1995) .
As an approach to inx estigating the role of TNF induction in the anti-tumour action of DNMXAA. wxe co-administered thalidomide wxith DMXAA to mice x ith subcutaneous Colon 38 tumours . Thalidomide. best knowxn for its sedatixe and teratogenic effects (Fabro et al. 1967) . has receixed attention in recent -ears as a selectixe inhibitor of TNT production Sampaio et al. 1991 ) . apparently acting, by increasing the rate of degradation of TNT m_RNA (Moreira et al. 1993) . We haxe shoxwn that thalidomide inhibits DMXAA-induced serum TNF lexels. but. unexpectedly. potentiates the anti-tumour response . While these results appear to argue against a role for TNF in the anti-tumour action of D.MXA. they indicate a noxvel approach to augmenting the anti-tumour action of DMXAA.
Recently. sexeral phthalimide-derixved analogues of thalidomide hax-e been described that are more potent than thalidomide in modulating TNF production in cells stimulated with a phorbol ester (Sasaki et al. 1995 
MATERIALS AND METHODS Materials
DMXAA. svnthesized in this laboratorv by Dr GA Rew-castle . w-as dissolved in 5%z7c sodium bicarbonate and xwas injected intraperitoneallv (i.p.) in a volume of 0.01 ml g-' bodv weight. (->-Thalidomide. N-phenylphthalimide (PP) . N-phenethylphthalimide (PEP). and N-phenethyltetrafluorophthalimide (PEFP) (chemical structures in Figure 1 ) w ere synthesized according to published methods (Casini and Ferappi. 1964: Sasaki et al. 1995 (Bagulev et al. 1989 ).
Determination of serum TNF
Mice were anaesthetized using halothane and wA-ere bled from the ocular sinus at indicated times after treatment. Blood w as allowed to clot ovemirht on ice and the serum collected by centrifu2ation (2000 g. 30 min) and stored at -20 C until it was assayed for TNF activity. using the standard L929 cvtotoxicitx assay as described (Philpott et al. 1995) . L929 cells (3 x 10-) were allowed to adhere ox erniht to the bottom of flat-bottomed 96-ell plates. Actinomycin D (final concentration 8 ,gr ml-') was then added to the wells followed by serial dilutions of the serum to be assayed. Killinc of the L929 cells was assessed after 24 h by a colorimetric assay using 3-(4.5-dimethvl-2-thiazoly l)-2.5-dipheny-l-2H-tetrazolium bromide. One unit of TNF A as defined as that reducing cell staining in this assay by 50%. and corresponded to the activitx obtained with 10-" of punrfied murine TNF protein.
British Joumal of Cancer (1998) . either alone (0) or together with thalidomide (100 mg kg-) (-) .
Comparisons of inhibition of serum TNF production w-ere carried out using a dose of DMXAA (50 mg kg-') that Awas optimal British Joumal of Cancer (1998) inhibited TNF lexels to 58. 18 and 8.5%k. respectively. of DMXVAA controls ( Figure 6 ). They xx-ere thus more potent than thalidomide.
"-hich was actix-e at a dose of 0.3 mg kg-. In contrast to thalidomide. none of the phthalimide derivatixves caused sedation (results not sho"-n).
We next compared the ability of the phthalimide analogues at a dose (10 mg kg-') that suppressed serum TNF production (Ficure 6) to potentiate the anti-tumour response of DMXAA (30mgr kg-). Combination of DMXAA A-ith PEFP and PP produced cures against the Colon 38 tumour in 100% of the mice (Ficure 7). A-hile combination with PEP caxve cures in 75%7e of the mice and extended the growth delay to oxer 60 days. At this dose. thalidomide "-as the least actix-e of the four agents. Thus. all three phthalimide derixatixes appeared to be more potent than thalidomide in potentiating the anti-tumour actix itv of DMXAA.
As PEFP "-as the most actix-e in reducing serum TNF lexels Ficure 6). A e tested this compound at low er doses for potentiation of the anti-tumour action. PEFP A. 1 mg kg-in combination "-ith DNIX.AA (30 mc kg-1) induced cures in 100%' of the animals (Figrure 8) and thus >-as at least 1000-fold more potent than thalidomide. A hich required a dose of 100 mc ko' in combination wvith DNMXAA for a 100% cure rate (Table 1) . PEFP had no antitumour effects on its ow n at its maximal-tolerated dose (Figure 8 ).
and this >-as also the case for PEP and PP (100 mg k-': data not shox-n).
Inhibition of serum TNF production and potentiation of DMXAA anti-tumour action by pentoxifylline The studies w-ith the phthalimide derixatixes extended our prexious demonstration that inhibition of serum DMXAAinduced TNF production xxas concomitant x-ith the potentiation of DMXAA anti-tumour action (Figures 6 and 7) . We therefore examined pentoxifylline. a structurallv unrelated inhibitor (Figyure 1). w-hich. like thalidomide. inhibits TNF production in response to lipopolx-saccharide (Noel et al. 1990 ). We found that co-administration of pentoxifylline at doses of 12.5-100 mg kg-1 reduced DMXAA-induced serum T'NF bv 50-805 (data not shown). Co-administration of pentoxifxlline (50 mg kgYincreased the growth delav induced by DNIXAA (30 mg kg-) from 19 to more than 40 dayvs ( Figure 9A ) and increased the cure rate from 64A' to 82%. but these differences were not statistically si2nificant. Co-administration of DNIXAA w-ith pentoxifylline (100 mg kgx-) induced complete tumour regressions in 100% of the mice ( Figure 9B   DISCUSSION W'e have previously demonstrated that thalidomide. w hile reducina DNIXAA-induced increases in serum TNF. potentiates the anti-tumour response of DNIXAA ). We have show n similar effects to thalidomide firstly for three derivatives of phthalimide structurally related to thalidomide (Sasaki et al. 1995) and secondly for pentoxifA-lline. w-hich differs from thalidomide in both structure and mechanism of TNT inhibition (Han et al. 1990 : Sampaio et al. 1991 . The augmentation of anti-tumour activitv bv these drugs (Figures 7-9 ) is difficult to assess statisticallv because DMXAA alone induces a percentage of cures. and a large number of animals are therefore required to achiex-e statisticall1 sienificant differences in cure rates. How-ever. taken together. the results are consistent w-ith the conclusion that the potentiation of the antitumour action of DMNXAA is associated w ith the common property of pentoxifylline. thalidomide and the phthalimides to decrease serum TNF production. Co-administration of agents low erincy serum TNF may thus represent an innoxvative strateav for increasing the anti-tumour efficacy of DMIX.AA. a drug that is currently in phase I clinical trial.
Thalidomide has a number of pharmacological actions. includinc the inhibition of angiogenesis (DAmato et al. 1994) . raisin2 the question of w hether potentiation of DMXAA actix ity is mediated by its anti-angiogenic properties. Administered alone. thalidomide had no inhibitorx effect on the row-th of the Colon 38 tumour . and repeated dosing did not affect the (D'Amato et al. 1994) . and it is likely that higher doses than that used in these experiments are necessarx for inhibition of neox ascularization (RJ d'Amato. personal communication) . W'hile we have not ruled out completely that thalidomide may be potentiating the anti-tumour activitv of DMXAA through inhibition of anaioeenesis. it appears more likely that it is acting in some other fashion.
Histoloaical studies indicate that the augmented tumour growth inhibition of the combined therapy stems from an acute effect resulting in a greater reduction in tumour cell survival at 24 h and from a subsequent slower rate of regeneration (Figure 4 . These obserx ations suggest that thalidomide minht in some w-ax increase the actions of the induced cvtokines.
The mechanism bx which thalidomide. the phthalimide derixatixes and pentoxifx lline inhibit serum TNF production is not vet British Joumal of Cancer (1998) 
